Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 393-400

  Dicenzo, Robert ^a,b   Luque, Amneris ^b   Larppanichpoonphol, Panupoong ^b   Reichman, Richard ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Drug monitoring; HIV antiviral pharmacology; Pharmacokinetics

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BILIRUBIN; COTRIMOXAZOLE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; PROTON PUMP INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MALE; MULTIVARIATE ANALYSIS;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BILIRUBIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIMIDINONES;

EID: 33748043297     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl238     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998; 338: 853-60.
2. Gerstoft J, Dragsted UB, Cahn P et al. Final analysis of a randomized trail to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: The MaxCmin1 trial. In: Programs and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract H-172, p. 263. American Society for Microbiology, Washington, DC, USA.
3. De Witt S, Boulme R, Konopnicki D et al. Nelfinavir (NFV): 12-month safety and efficacy vs. boosted-indinavir (IDV/RTV), each in combination with 2 NRTIs, in treatment naïve patents. In: Programs and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract H-168, p. 262. American Society for Microbiology, Washington, DC, USA.
4. Burger DM, Hugen PW, Droste J et al. Therapeutic drug monitoring (TDM) of indinavir and nelfinavir in treatment-naive patients improves therapeutic outcome after 1 year: Results from ATHENA. In: Programs and Abstacts of the Second International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands, 2001. Abstract 6.2a and 6.2b.
5. Shulman N, Zolopa A, Havlir D et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patents with ongoing viremia. Antimicrob Agents Chemother 2002; 46: 3907-16.
6. Frerichs VA, DiFrancesco R, Morse GD. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 787: 393-403.
7. Abbott Laboratories. Kaletra Prescriber Information. North Chicago, IL: Abbott Laboratories, 2005.
8. Harris A, Alexander C, Ting L et al. Rescue therapy with indinavir (IDV) 600 mg twice daily and lopinavir/ritonavir (LPV/RTV): Baseline resisitance, virologic response and pharmaokinetics (PK). In: Programs and Abstracts of the Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2002. Abstract P170.
9. Antoniou T, Tseng A, van Heeswijk R et al. Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients. Ther Drug Monit 2005; 27: 779-81.
10. Von Hentig N, Dauer B, Moesch M et al. Indinavir plasma exposure is not affected by ritonavir/lopinavir co-administration in a boosted double PI-only therapy regimen. In: Programs and Abstracts of the Ninth European AIDS Conference, Warsaw, Poland, 2003. Abstract 9.
11. Poirier JM, Meynard JL, Zouai O et al. Lack of alteration of lopinavir and indinavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and Crixivan. In: Programs and Abstracts of the Fifth International Workshop on Clinical Pharmacology of HIV, Rome, Italy, 2004. Abstract 4.2.
12. Isaac A, Taylor S, Cane P et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: Pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother 2004; 54: 498-502.
13. Bertz RG, Foit C, Ashbrenner E et al. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. In: Programs and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1822, p. 26. American Society for Microbiology, Washington, DC, USA.
14. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. (7 April 2005, date last accessed).
15. Dieleman JP, Sturkenboom M, Jambroes M et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: The ATHENA cohort. Arch Intern Med 2002; 162: 1493-501.
16. Dieleman JP, Gyssens IC, van der Ende ME et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8.
17. Quirk E, McLeod H, Powderly W. The pharmacogenetics of antiretroviral therapy: A review of studies to date. Clin Infect Dis 2003; 39: 98-106.
18. Zucker SD, Qin X, Rouster SD et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci 2001; 98: 12671-6.
19. Rayner C, Esch LD, Wynn HE et al. Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. Ann Pharmacother 2001; 35: 1391-5.
20. Vernon R, Daudon M, Albessard F et al. Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus. Clin Infect Dis 2002; 35: 57-9.
21. Gonzales de Requena D, Nunez M, Jimenez-Nacher I et al. Short communication: Liver toxicity of lopinavir/ritonavir-containing regimens in HIV-infected patients with or without hepatitis C co-infection. AIDS Res Hum Retroviruses 2004; 20: 698-700.
22. Canta F, Marrone R, Bonora S et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother 2005; 55: 280-1.
23. Solas C, Poizot-Martin I, Drogoul M et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol 2003; 57: 436-40.
24. Seminari E, Gentilini G, Galli L et al. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J Antimicrob Chemother 2005; 56: 790-2.
25. Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821-6.
26. Livry C, Binquet C, Sgro C et al. Acute liver enzyme elevations in HIV-1-infected patients. HIV Clin Trials 2003; 4: 400-10.
27. Meraviglia P, Schiavini M, Castagna A et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: Evaluation of risk factors for liver enzyme elevation. HIV Med 2004; 5: 334-43.
28. Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep 2005; 2: 39-50.